AbbVie’s Venclyxto OK’d in Europe for CLL
Patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL) have gained a new treatment option after the European Commission issued a green light for AbbVie’s Venclyxto.
Read More
Tag: BCR inhibitor
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
